Table of Contents
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Travel Vaccines Market to 2019: Introduction
2.1 Overview
3 Travel Vaccines Market to 2019: Overview
3.1 Vaccine-Preventable Diseases
3.1.1 Types of Vaccines
3.2 Regulatory Framework
3.2.1 US
3.2.2 UK
3.2.3 France
3.2.4 Germany
3.2.5 Italy
3.2.6 Spain
3.2.7 Japan
3.3 Vaccine Manufacturing Process
4 Travel Vaccines Market to 2019: Market Characterization and Forecast
4.1 Revenue Forecast
4.2 Market Share by Vaccine Type
4.3 Market Share by Geography
4.4 Traveling Population
4.5 Drivers
4.5.1 Aging Population and Increase in Global Tourist Traffic
4.5.2 Novel Vaccine Technologies
4.5.3 New and Novel Vaccines Launches Targeting High-Risk Populations
4.6 Restraints
4.6.1 Vaccine Supply Shortage Issues
4.6.2 High Start-up Costs and Special Technical Expertise Requirements for Vaccine Production
4.6.3 Public Acceptance
4.6.4 Austerity Measures Leading to a Drop in Healthcare Funding
5 Travel Vaccines Market to 2019: Hepatitis A Vaccines
5.1 Disease Overview
5.2 Market Forecasts
5.2.1 US
5.2.2 Top Five European Countries
5.2.3 Japan
5.3 Cost of Vaccination
5.3.1 US
5.3.2 Top Five European Countries
5.3.3 Japan
5.4 Pipeline Analysis
5.4.1 Phase III (Inactive)
5.4.2 Preclinical and Discovery (Inactive)
6 Travel Vaccines Market to 2019: Hepatitis B Vaccines
6.1 Disease Overview
6.2 Market Forecasts
6.2.1 US
6.2.2 Top Five European Countries
6.2.3 Japan
6.3 Cost of Vaccination
6.3.1 US
6.3.2 Top Five European Countries
6.3.3 Japan
6.4 Pipeline Analysis
6.4.1 Registration and Phase III
6.4.2 Phase II
6.4.3 Phase I
6.4.4 Preclinical and Discovery
7 Travel Vaccines Market to 2019: Japanese Encephalitis Vaccines
7.1 Disease Overview
7.2 Market Forecasts
7.2.1 US
7.2.2 Top Five European Countries
7.2.3 Japan
7.3 Cost of Vaccination
7.3.1 US
7.3.2 Top Five European Countries
7.3.3 Japan
7.4 Pipeline Analysis
7.4.1 Registration
7.4.2 Preclinical and Discovery
8 Travel Vaccines Market to 2019: Meningococcal Vaccines
8.1 Disease Overview
8.2 Market Forecasts
8.2.1 US
8.2.2 Top Five European Countries
8.3 Cost of Vaccination
8.3.1 US
8.3.2 Top Five European Countries
8.4 Pipeline Analysis
8.4.1 Registration and Phase III
8.4.2 Phase II
8.4.3 Preclinical and Discovery
9 Travel Vaccines Market to 2019: Rabies Vaccines
9.1 Disease Overview
9.2 Market Forecasts
9.2.1 US
9.2.2 Top Five European Countries
9.2.3 Japan
9.3 Cost of Vaccination
9.3.1 US
9.3.2 Top Five European Countries
9.3.3 Japan
9.4 Pipeline Analysis
9.4.1 Phase II
9.4.2 Phase I
9.4.3 Preclinical
10 Travel Vaccines Market to 2019: Typhoid Vaccines
10.1 Disease Overview
10.2 Market Forecasts
10.2.1 US
10.2.2 Top Five European Countries
10.3 Cost of Vaccination
10.3.1 US
10.3.2 Top Five European Countries
10.4 Pipeline Analysis
10.4.1 Phase II
10.4.2 Preclinical
11 Travel Vaccines Market to 2019: Yellow Fever Vaccines
11.1 Disease Overview
11.2 Market Forecasts
11.2.1 US
11.2.2 Top Five European Countries
11.2.3 Japan
11.3 Cost of Vaccination
11.3.1 US
11.3.2 Top Five European Countries
11.3.3 Japan
11.4 Pipeline Analysis
11.4.1 Phase III
11.4.2 Phase I
11.4.3 Preclinical and Discovery
12 Travel Vaccines Market to 2019: Competitive Landscape
12.1 Introduction
12.2 Major Company Profiles
12.2.1 GlaxoSmithKline
12.2.2 Sanofi
12.2.3 Pfizer
12.2.4 Merck
12.2.5 Novartis
13 Travel Vaccines Market to 2019: Strategic Consolidations
13.1 Deals by Year
13.2 Deals by Type
13.3 Deals by Value
13.4 Deals by Geography
13.5 Summary of Major M&A Deals
13.5.1 Gilead Sciences Completes Acquisition of Pharmasset for $11.2 Billion
13.5.2 Johnson & Johnson Acquires Crucell
13.6 Summary of Major Licensing Deals
13.6.1 Intercell Enters into Licensing Agreement with Novartis for IC51
13.6.2 Gilead Sciences Enters into Licensing Agreement with GlobeImmune
14 Vaccines in Asia-Pacific – India, China and Australia: Overview
14.1 India
14.1.1 Regulatory Framework
14.1.2 Major Company Profiles
14.2 Recent Developments
14.2.1 Biological E. Launches Japanese Encephalitis Vaccine Jeev in India – September 2012
14.2.2 Approvals by Central Drugs Standard Control Organization
14.3 China
14.3.1 Regulatory Framework
14.3.2 Expanded Programme on Immunization
14.3.3 Major Company Profiles
14.4 Australia
14.4.1 Regulatory Framework
14.4.2 Designated Vaccines and Circumstances in which Vaccines may be Provided
14.4.3 Immunization Schedule
14.4.4 Major Company Profiles
14.4.5 Recent Developments
14.5 Vaccines in Emerging Markets: Strategic Consolidations
14.5.1 Deals by Year
14.5.2 Deals by Type
14.5.3 Deals by Value
14.6 Vaccines in Emerging Markets: Pipeline by Phase
15 Travel Vaccines Market to 2019: Appendix
15.1 Market Definitions
15.2 Abbreviations
15.3 Bibliography
15.4 Research Methodology
15.4.1 Coverage
15.4.2 Secondary Research
15.4.3 Primary Research
15.4.4 Model for Estimation of Vaccine Market
15.5 Geographical Landscape
15.6 Pipeline Analysis
15.7 Competitive Landscape
15.7.1 Expert Panel Validation
15.8 Contact Us
15.9 Disclaimer